BRAF Mutation and Cancer - Johns Hopkins Medicine
Scientists have identified many different types of BRAF mutations. One of the most common types is the BRAF V600E mutation. The name V600E describes the nature and location of the …
V600E - Wikipedia
V600E is a mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at amino acid 600. [1][2] It is a driver mutation in a proportion of certain diagnoses, including …
BRAF V600E -mutant metastatic NSCLC: disease overview and
Apr 16, 2024 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging …
FDA approves dabrafenib–trametinib for BRAF-positive cancers
Jul 21, 2022 · FDA previously approved the dabrafenib–trametinib combination for the treatment of people with advanced forms of specific cancers whose tumors have the BRAF V600E …
BRAF V600E -mutant metastatic NSCLC: disease overview and
Apr 16, 2024 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging …
Real-world first-line treatment of patients with BRAF V600E
This study is, to date, the largest real-world analysis of patients with BRAF V600E -mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients.
Targeting BRAF V600E in metastatic colorectal cancer: where are …
The BRAF V600E mutation, considered the most common alteration of BRAF, corresponds to a constitutive kinase with a high activating capacity of the RAS/RAF/MEK/ERK pathway after a …
Phase III trial results supported recent FDA approval for patients …
5 days ago · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus …
Management of asynchronous multifocal adult glioblastoma with loss of BRAF
3 days ago · The BRAF V600E mutation is targetable with FDA-approved small molecule inhibitors [4], and when employed, can improve the survival in appropriately selected patients …
BRAFV600E: implications for carcinogenesis and molecular therapy
Here, the role of the most common BRAF mutation BRAF (V600E) in human carcinogenesis is investigated through a review of the literature, with specific focus on its role in melanoma, …